May 2004
Volume 45, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2004
Iritis prevention study: does topical flurbiprofen prevent recurrent iritis in patients at high risk?
A. Hall; R.J. Stawell; D. Manning; F. Murphy; M.–L. Tay–Kearney; D. Conrad; L. Lim
Author Affiliations & Notes
  • A. Hall
    Royal Victorian Eye and Ear Hospital, Ocular Immunology Clinic, East Melbourne, Australia
  • R.J. Stawell
    Royal Victorian Eye and Ear Hospital, Ocular Immunology Clinic, East Melbourne, Australia
  • D. Manning
    Royal Victorian Eye and Ear Hospital, Ocular Immunology Clinic, East Melbourne, Australia
  • F. Murphy
    Royal Victorian Eye and Ear Hospital, Ocular Immunology Clinic, East Melbourne, Australia
  • M.–L. Tay–Kearney
    Royal Perth Hospital, Perth, Australia
  • D. Conrad
    Mater Hospital, Brisbane, Australia
  • L. Lim
    Royal Victorian Eye and Ear Hospital, Ocular Immunology Clinic, East Melbourne, Australia
  • Footnotes
    Commercial Relationships  A. Hall, Allergan Australia F; R.J. Stawell, Allergan Australia F; D. Manning, None; F. Murphy, None; M. Tay–Kearney, None; D. Conrad, None; L. Lim, None.
  • Footnotes
    Support  none
Investigative Ophthalmology & Visual Science May 2004, Vol.45, 1005. doi:
  • Views
  • Share
  • Tools
    • Alerts
      User Alerts
      You are adding an alert for:
      Iritis prevention study: does topical flurbiprofen prevent recurrent iritis in patients at high risk?
      You will receive an email whenever this article is corrected, updated, or cited in the literature. You can manage this and all other alerts in My Account
      The alert will be sent to:
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation
      Citation

      A. Hall, R.J. Stawell, D. Manning, F. Murphy, M.–L. Tay–Kearney, D. Conrad, L. Lim; Iritis prevention study: does topical flurbiprofen prevent recurrent iritis in patients at high risk? . Invest. Ophthalmol. Vis. Sci. 2004;45(13):1005.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

      ×
    • Get Permissions
  • Supplements
Abstract

Abstract: : Purpose: To determine the effect of prophylactic long term topical NSAIDs on recurrent iritis. Methods: Randomised controlled multicentre clinical trial. Patients with a history of frequently recurrent iritis were randomised to topical flurbiprofen 300 mcg/ml (Ocufen, Allergan Australia) or placebo twice daily to both eyes. Patients were followed three monthly and treated for one year. The incidence of recurrent iritis and side effects were determined and Kaplan Meier relapse free survival curves were compared between the treated and placebo patients. Results: 64 patients were treated (30 active and 34 control). Average age 38.1 yrs. Average treatment time 169 days. Median time to iritis relapse in the treated and placebo arms were 276 and 258 days respectively (P= 0.97). 7/30 treated patients and 0/34 control patients had increased stinging. Conclusions: The use of long term prophylactic topical flurbiprofen does not statistically significantly reduce iritis recurrence.

Keywords: uveitis–clinical/animal model • pharmacology • autoimmune disease 
© 2004, The Association for Research in Vision and Ophthalmology, Inc., all rights reserved. Permission to republish any abstract or part of an abstract in any form must be obtained in writing from the ARVO Office prior to publication.
Copyright © 2025 Association for Research in Vision and Ophthalmology.
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×
This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy.Accept